2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory

Why It Matters

These dividend‑rich pharma leaders provide income stability and growth potential when tech‑heavy equities falter, helping investors hedge recession risks. Their resilient cash flows and pipeline advancements support sustained shareholder returns.

Key Takeaways

• AbbVie yields 3.18% with $369B market cap.
• Skyrizi and Rinvoq projected $31B sales 2026.
• Amgen yields 2.78% and explores weight‑loss market.
• Both firms offer defensive dividend profiles amid Nasdaq dip.
• Pipeline diversification reduces recession risk for investors.

Pulse Analysis

The recent slide in the Nasdaq Composite, now flirting with correction territory, has revived interest in defensive sectors that can cushion portfolios against macro volatility. Healthcare, with its steady demand and regulatory tailwinds, stands out as a reliable haven, especially for income‑focused investors. Dividend‑paying drugmakers combine cash flow resilience with shareholder returns, offering a counterbalance to the tech‑driven turbulence that has dominated market headlines. As recession fears linger, capital rotation toward high‑yield, low‑beta stocks is becoming a prudent tactical move for both retirees and long‑term growth seekers.

AbbVie (ABBV) exemplifies the dividend‑centric model, trading around $209 per share with a 3.18% yield and a $369 billion market capitalization. Its immunology duo Skyrizi and Rinvoq is slated to generate more than $31 billion in sales by 2026, underpinning earnings growth despite broader economic headwinds. The company’s Botox franchise adds a moat, as the complex molecule deters biosimilar competition, securing a steady revenue stream. As a Dividend King with over five decades of payout hikes, AbbVie offers investors a blend of income stability and upside potential from a diversified pipeline.

Amgen (AMGN) presents a complementary case, priced near $348 with a 2.78% dividend and a $188 billion market cap. While the loss of Prolia’s patent pressures short‑term sales, the firm’s portfolio—featuring Tezspire and Repatha—continues to drive revenue growth. Crucially, Amgen’s Phase 3 GLP‑1 candidate MariTide positions it to capture a slice of the booming weight‑loss market, potentially adding a high‑margin growth engine. Consistent dividend increases since 2011 reinforce its appeal to income investors, making Amgen a solid defensive play amid ongoing market uncertainty.